Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis

PHASE2TerminatedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Plaque Psoriasis
Interventions
DRUG

PF-04965842

Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks

DRUG

PF-04965842

Subjects will receive 400 mg PF 04965842 daily for 4 weeks

DRUG

PF-04965842

Subjects will receive 200 mg PF 04965842 daily for 4 weeks

OTHER

Placebo

Subjects will receive placebo for 4 weeks

Trial Locations (45)

10029

Mount Sinai Medical Center, New York

23507

Virginia Clinical Research, Norfolk

27262

Dermatology Consulting Services, High Point

27710

Duke University Medical Center - Shipment Only, Durham

Duke University Medical Center, Durham

30342

Advanced Medical Research, Inc, Atlanta

31904

Columbus Dermatology, P.C., Columbus

Columbus Regional Research Institute, Columbus

32073

Park Avenue Dermatology, PA, Orange Park

32174

Leavitt Medical Associates of Florida d/b/a Ameriderm Research, Ormond Beach

32204

North Florida Dermatology Associates, PA, Jacksonville

32505

Total Skin and Beauty Dermatology Center, PC, Birmingham

33144

International Dermatology Research, Inc., Miami

33756

Olympian Clinical Research, Clearwater

Westcoast Radiology Services, Clearwater

40202

DS Research, Louisville

46256

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

Dawes Fretzin Dermatology Group, LLC, Indianapolis

57702

Health Concepts, Rapid City

60118

Dundee Dermatology, West Dundee

70605

Shondra L Smith, MD, Lake Charles

72758

Northwest Arkansas Clinical Trials Center, PLLC/Hull Dermatology, PA, Rogers

73112

Lynn Health Science Institute, Oklahoma City

75230

Dermatology Treatment & Research Center, PA, Dallas

76011

Arlington Research Center, Inc., Arlington

77004

Center for Clinical Studies, Houston

90045

Dermatology Research Associates, Los Angeles

90404

Clinical Science Institute, Santa Monica

91105

Huntington Medical Foundation/Specialty Office, Pasadena

92024

California Dermatology & Clinical Research Institute, Encinitas

92056

Dermatology Specialists, Inc., Oceanside

01605

Clinical Pharmacology Study Group, Worcester

03756

Dartmouth-Hitchcock Medical Center - Section of Dermatology, Lebanon

02919

Clinical Partners, LLC, Johnston

99202-1480

Premier Clinical Research, Spokane

V3V 0C6

Enverus Medical Research, Surrey

L1E 3C3

Co-Medica Research Network Inc., Courtice

L3P 1X2

Lynderm Research Inc., Markham

L6J 7W5

Research by ICLS, Oakville

K9J 5K2

SKiN Centre for Dermatology, Peterborough

L4B 1A5

The Centre for Dermatology & Cosmetic, Richmond Hill

N2J 1C4

K.Papp Clinical Research Inc., Waterloo

J2B 5L4

Dr Isabelle Delorme Inc., Drummondville

H2K 4L5

Innovaderm Research Inc., Montreal

J1J 2G2

Q & T Research Sherbrooke Inc., Sherbrooke

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02201524 - Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis | Biotech Hunter | Biotech Hunter